HUMA vs. EVLV, DSKE, BARK, SST, BODY, SWTX, APGE, IOVA, ACLX, and DNLI
Should you be buying Humacyte stock or one of its competitors? The main competitors of Humacyte include Evolv Technologies (EVLV), Daseke (DSKE), BARK (BARK), System1 (SST), Beachbody (BODY), SpringWorks Therapeutics (SWTX), Apogee Therapeutics (APGE), Iovance Biotherapeutics (IOVA), Arcellx (ACLX), and Denali Therapeutics (DNLI).
Humacyte (NASDAQ:HUMA) and Evolv Technologies (NASDAQ:EVLV) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, community ranking, risk and dividends.
44.7% of Humacyte shares are owned by institutional investors. Comparatively, 66.7% of Evolv Technologies shares are owned by institutional investors. 23.1% of Humacyte shares are owned by company insiders. Comparatively, 11.2% of Evolv Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Humacyte has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, Evolv Technologies has a beta of 1.37, suggesting that its stock price is 37% more volatile than the S&P 500.
In the previous week, Humacyte had 2 more articles in the media than Evolv Technologies. MarketBeat recorded 7 mentions for Humacyte and 5 mentions for Evolv Technologies. Evolv Technologies' average media sentiment score of 1.43 beat Humacyte's score of 0.80 indicating that Evolv Technologies is being referred to more favorably in the news media.
Humacyte currently has a consensus target price of $8.00, indicating a potential upside of 6.95%. Evolv Technologies has a consensus target price of $5.65, indicating a potential upside of 97.55%. Given Evolv Technologies' higher possible upside, analysts clearly believe Evolv Technologies is more favorable than Humacyte.
Evolv Technologies has higher revenue and earnings than Humacyte. Humacyte is trading at a lower price-to-earnings ratio than Evolv Technologies, indicating that it is currently the more affordable of the two stocks.
Humacyte has a net margin of 0.00% compared to Evolv Technologies' net margin of -106.93%. Evolv Technologies' return on equity of -45.57% beat Humacyte's return on equity.
Humacyte received 7 more outperform votes than Evolv Technologies when rated by MarketBeat users. However, 83.33% of users gave Evolv Technologies an outperform vote while only 51.52% of users gave Humacyte an outperform vote.
Summary
Evolv Technologies beats Humacyte on 11 of the 17 factors compared between the two stocks.
Get Humacyte News Delivered to You Automatically
Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HUMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Humacyte Competitors List
Related Companies and Tools
